SymbioCellTech submits INTERACT Package to FDA Center for Biologics Evaluation and Research (CBER)

Written By SymbioCellTech, LLC

After demonstrating initial pre-clinical safety and efficacy in both rodents and pet dogs, today, SymbioCellTech, LLC, a Salt Lake City, Utah based biotechnology company submitted a complete INTERACT Package to the FDA Center for Biologics Evaluation and Research (CBER) in preparation for their Investigational New Drug (IND) application to begin human trials using their proprietary “Neo-Islet” technology to cure Type I Diabetes.

SymbioCellTech, LLC
Previous

SymbioCellTech Greenlighted to Submit FDA Pre-IND to CBER
Next

SymbioCellTech Presents Preliminary Data from First-of-Its-Kind Dog Study at American Diabetes Association Meeting